Sep 28, 2005 (financialwire.net via COMTEX) --

September 28, 2005 (FinancialWire) MIV Therapeutics (OTCBB: MIVT) gained 26.13% on volume of 682,160, slightly higher than its usual 624,059, to close at $1.40.

MIV Therapeutics is covered by Investrend Research affiliate Beacon Equity Research analyst Shailesh Dhuri, who on April 6, 2005, rated the company "Outperform," with a Target of $1.53. The company was previously covered by Investrend Research affiliate SISM Research's analyst, Ernest C. Schlotter. On February 15, 2005 Schlotter reinforced his coverage with a Speculative Buy/4 rating with a 12-month price target of $1.50, which was reiterated June 29, 2005. SISM Research is also distributed by the Investrend Research Syndicate. Beacon Equity Research, SISM Research and Investrend Research all subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and adhere to the Guidelines for independent providers jointly endorsed by the National Investor Relations Institute (http://www.niri.org) and the CFA Institute (http://www.cfainstitute.org)

According to the New York Times (NYSE: NYT), a survey by Charles Schwab & Co. reveals an astonishing 78 percent of active stockholders now "value research from independent firms over analysis by Wall Street firms with financial ties to the companies they are rating." A survey at Investopedia reveals that 74.7% of investors say that "legitimate fee-based research is objective and useful," and 70.9% say that a company that enrolls for "legitimate fee-based research is making a positive statement about its investment potential."

The fee for SISM coverage is $1,750 per month, and the fees are paid by the company to SISM. There are never any fees associated with FinancialWire, which independently covers a wide range of corporate news, including but not limited to those that are or have been enrolled in Investrend's platforms. The fee for Beacon Equity Research coverage is $18,000 for a year, and was paid by the company.

Complete information about any company enrolled in an Investrend Research affiliate platform, including disclosures and disclaimers, is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes , and on each report and press release, and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.

For up-to-the-minute news, features and links click on http://www.financialwire.net

FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp

For a free annual report on a company mentioned in the news, please click on http://investrend.ar.wilink.com/?level=279

The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268

http://www.financialwire.net